Navigation Links
Aragon Pharmaceuticals Announces $8 Million Series A Financing
Date:5/20/2009

s. Breakthrough science has created the opportunity for Aragon to solve the problem of treatment resistance by creating a new approach to hormone receptor therapy."

"Aragon will build off the work of our founders and focus on the discovery and development of compounds that target the degradation of the androgen and estrogen receptor, to treat patients with hormone refractory disease," stated Dr. Richard Heyman. "The company has recruited an experienced drug discovery team and several world-renowned scientists to the Scientific Advisory Board to help guide the discovery and development of our research programs."

Peter Svennilson noted, "It is the caliber of the people behind Aragon and the tremendous potential that this approach has for treating hormone dependent cancers that excited us about funding this opportunity. The Aragon team is poised to generate a pipeline of novel cancer therapies and I look forward to working with Aragon to achieve their vision to effectively treat hormone refractory cancers."

For more information, please see:

http://www.aragonpharmaceuticals.com

or email:

info@aragonpharmaceuticals.com


'/>"/>
SOURCE Aragon Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
2. Paragon Medsystems Becomes California MedTech
3. Paragon Benefits, Inc. Selects North Star Health for Data Analysis and Cost Management Reporting
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... , ATLANTA, Sept. 4 Blue Cross Blue Shield of ... already available to its group life insurance beneficiaries by offering a new ... loved one - The Healing Book: Facing the Death and Celebrating ... published by Watering Can Press). , , The ...
... , , , ... Access(SM), the nation,s leading provider of vascular access management services, ... awarded the 2009 Gerald A. Beathard Fellowship in Interventional Nephrology. ... pioneers in Interventional Nephrology and Lifeline,s Vice President of Provider ...
... Kan., Sept. 4 The path to poor hand sanitation is ... North Carolina State Universities. , , As college ... the researchers said students, actions will speak louder than words. , ... hands," said Douglas Powell, an associate professor of food safety at ...
... researchers have developed a new approach to identify ... to drugs and how they become resistant. This ... result in leukemia and associating specific mutations with ... how drug resistance occurs in leukemia and other ...
... ABBOTT PARK, Ill., Sept. 4 For the fourth consecutive year, Abbott (NYSE: ... to Launch a Career" by BusinessWeek magazine. The list highlights ... year, Abbott moved up to No. 13, and was once again the top-ranked ... list every year since BusinessWeek initiated the list in 2006. , ...
... suggests officials might need to rethink strategies , ... that officials in the United States, United Kingdom and ... because the current strategies -- emphasizing healthy diets and ... online Sept. 4 in BMJ , Australian researchers ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Georgia Offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with Losing a Loved One 2Health News:Gerald A. Beathard Fellowship Awarded to Dr. Stephen Osaguona 2Health News:Gerald A. Beathard Fellowship Awarded to Dr. Stephen Osaguona 3Health News:Getting College Students To Wash Hands, Halt Disease, Requires Giving Them Proper Tools and Spreading The Word In Ways That Get Attention, Say K-State Expert and Colleague 2Health News:New research strategy for understanding drug resistance in leukemia 2Health News:New research strategy for understanding drug resistance in leukemia 3Health News:Abbott Again Named One of the 'Best Places to Launch a Career' by BusinessWeek 2Health News:Abbott Again Named One of the 'Best Places to Launch a Career' by BusinessWeek 3
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 ... , offers Los Angeles a premier ... Duality laser and a $99 treatment special. Dr. Brandeis, focus ... medical technology and offering expert medical advice to all patients. ... a dramatic increase in the presence of tattoo regret and ...
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ... when air is thin," states Dr Barnes. She goes on to ...
(Date:1/14/2014)... --  Oligomerix, Inc. , a privately held company ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of ... additional laboratory space at New York Medical College. ... development of small molecule drugs aimed specifically at ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... EORTC 40983 (EPOC),Intergroup Study Results, CHICAGO, June ... phase III EORTC 40983 Intergroup study, or ... peri-operative (pre and post,surgery) FOLFOX4 (Eloxatin(R) (oxaliplatin ... for colon cancer,5-fluorouracil/leucovorin (5-FU/LV)) given to patients ...
... Phase II Study Results Presented at Society ... 04, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... with the radioisotope,iodine-131, was found to be ...
Cached Medicine Technology:The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 2The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 3The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 4The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 5The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 6The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 8The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 9Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
Superior comfort and flexibility are achieved through the revolutionary air pocket technology in the dimpled, ultra-thin SoftFlex skin barrier along with a discreet pouch shape and size....
Inquire...
Inquire...
Flextend is a hydrocolloid skin barrier that is designed to be the most resistant to discharge and is the barrier of choice for urostomies and high output ileosotomies....
Medicine Products: